March 5 (Reuters) – Tenaya Therapeutics said on Thursday it has signed a research deal with Alnylam Pharmaceuticals worth up to $1.13 billion to develop treatments for heart diseases. Shares of Tenaya were up more than 11% in premarket trading. Here are some details: * Tenaya said it will work on heart disease–focusedtreatments that target […]
Health
Tenaya Therapeutics inks $1.13 billion deal with Alnylam for heart-disease treatments
Audio By Carbonatix
March 5 (Reuters) – Tenaya Therapeutics said on Thursday it has signed a research deal with Alnylam Pharmaceuticals worth up to $1.13 billion to develop treatments for heart diseases.
Shares of Tenaya were up more than 11% in premarket trading.
Here are some details:
* Tenaya said it will work on heart disease–focusedtreatments that target up to 15 genetic causes during a two‑yearresearch period. * Alnylam will handle all further drug development and takefull responsibility for commercialization of any medicines thatcome out of the collaboration, Tenaya said. * The company said it could receive up to $10 million inupfront payments and additional research funding from Alnylam.It may also be eligible for up to $1.13 billion in milestonepayments if the drugs are successfully developed and approved. * Alnylam’s major growth driver is Amvuttra, which treats aheart condition known as transthyretin amyloid cardiomyopathy(ATTR-CM). Amvuttra recorded sales of $2.31 billion in 2025.
(Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Devika Syamnath)